李鹏
成都市清白江区人民医院,四川成都610000
[摘要]目的:探讨对老年骨质疏松性骨折患者采用鲑鱼降钙素与唑来膦酸进行联合治疗后的效果。方法:选取自2018年3月至2020年3月期间在我院接受治疗的老年骨质疏松性骨折患者92例作为本次的研究对象,将其分为两组,对照组(46例患者)采用唑来膦酸进行治疗与观察组(46例患者)采用鲑鱼降钙素与唑来膦酸进行治疗,两组患者治疗后的临床效果进行评测对比。结果:治疗前两组患者VAS及BMD之间的差异不具有显著性(P>0.05),经治疗,观察组患者的VAS数值较对照组更低,BMD数值较对照组更高,组间具有显著性差异(P<0.05);观察组治疗后不良反应发生率为13.04%,对照组治疗后不良反应发生率为21.74%,前者较后者更低,组间不具有显著性差异(P>0.05)。结论:对老年骨质疏松性骨折患者采用鲑鱼降钙素与唑来膦酸进行联合治疗后,有效改善患者的临床症状,减轻疼痛及增加骨密度,具有较少的不良反应。
关键词:鲑鱼降钙素;唑来膦酸;老年骨质疏松性骨折;临床疗效
老年骨质疏松骨折疾病对患者的生活质量带来极大的影响,降低了患者的身心健康。临床上常采用手术对其进行治疗,在术后极易造成骨丢失及加重骨质疏松,因此在术后采用相应的药物治疗,可有效提高术后的治疗疗效,改善患者的临床症状及骨质疏松状况[1]。本次研究将针对老年骨质疏松性骨折患者采用鲑鱼降钙素与唑来膦酸进行联合治疗后的疗效进行分析:
1资料与方法
1.1临床资料
选取自2018年3月至2020年3月期间在我院接受治疗的老年骨质疏松性骨折患者92例作为本次的研究对象,将其分为两组,对照组(46例患者)采用唑来膦酸进行治疗与观察组(46例患者)采用鲑鱼降钙素与唑来膦酸进行治疗。对照组中男女患者比例为26:20,均位于61-78岁年龄段之间,所测均值(67.24±2.11)岁;观察组中男女患者比例为30:16,均位于62-80岁年龄段之间,所测均值(68.95±1.87)岁。两组患者之间的基线资料进行对比后无显著性差异(P>0.05),提示组间可进行对比。本次研究患者均被确诊为老年骨质疏松性骨折疾病,患者及其家属均自愿加入本次研究且签署知情同意书,排除依从性较差的患者。本次研究经过我院伦理委员会批准。
1.2治疗方法
两组患者均行手术治疗。
对照组:将5ml的唑来膦酸与100ml的氯化钠溶液进行配比,将其对患者进行静脉滴注,滴注时间应大于15min。每月一次。
观察组:唑来膦酸的用法用量与对照组一致。另相对患者进行鲑鱼降钙素的皮试,观察显示阴性后,将剂量为50U的鲑鱼降钙素进行皮下注射,每日一次。随着病情的发展,可将剂量进行调整,剂量最大不超过100U。两组患者均接受2个月的治疗。
1.3观察指标
(1)两组患者治疗前后VAS及BMD评测对比。(2)两组患者治疗后不良反应评测对比。
1.4统计分析
实验测得结果以SPSS22.0录入评测。计量指标指以(x±s)的形式表述,经t值对结果检验;计数指标在表示时用(%)形式,经卡方值对结果检验,检验值为P<0.05提示统计学差异显著。
2结果
2.1两组患者治疗前后VAS及BMD评测对比
治疗前两组患者VAS及BMD之间的差异不具有显著性(P>0.05),经治疗,观察组患者的VAS数值较对照组更低,BMD数值较对照组更高,组间具有显著性差异(P<0.05)。见表1。
表1 两组患者治疗前后VAS及BMD评测对比()
![](data:image/png;base64,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)
2.2两组患者治疗后不良反应评测对比
观察组治疗后不良反应发生率为13.04%,对照组治疗后不良反应发生率为21.74%,前者较后者更低,组间不具有显著性差异(P>0.05)。见表2。
表2 两组患者治疗后不良反应评测对比[n(%)]
![](data:image/png;base64,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)
3讨论
骨质疏松代表患者体内骨密度降低,易出现由该病导致的骨折。该疾病好发于老年人群,导致患者出现致残及致死的情况[2]。使用唑来膦酸进行治疗,主要是由于该药物进入体内后将骨吸收进行抑制,从而提升骨密度,使患者术后出现并发症的几率较少,保证患者的术后效果。鲑鱼降钙素对破骨细胞活性进行机制,相反能对骨细胞活性具有加强的功效,可促使骨形成,降低骨量流失的作用,从而达到治疗目的[3]。
本次研究中,观察组患者的VAS数值较对照组更低,BMD数值较对照组更高(P<0.05),不良反应较对照组更低(P>0.05),该结果显示,观察组的方案能有效减轻患者的疼痛,增强患者的骨密度,具有更佳的治疗效果,治疗后出现的不良反应较对照组更少,相对而言安全性更高。
综上所述,对老年骨质疏松性骨折患者采用鲑鱼降钙素与唑来膦酸进行联合治疗后,有效改善患者的临床症状,减轻疼痛及增加骨密度,具有较少的不良反应。
参考文献
[1] 马森, 欧阳晟, 任书信. 降钙素联合唑来膦酸治疗老年骨质疏松性骨折的疗效[J]. 中国执业药师, 2019, 016(008):137-140.
[2] 郭子旭. 唑来膦酸联合降钙素治疗老年骨质疏松性骨折的临床效果及安全性[J]. 临床合理用药杂志,2020,13(22):51-52.
[3] 季康,张中伟,徐红伟. 唑来膦酸注射液联合降钙素治疗老年骨质疏松的疗效及其对血清IL-6、TNF-α水平的影响[J]. 中国老年学杂志,2020,40(02):356-359